6414 related articles for article (PubMed ID: 21809660)
1. [Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB; Lichinitser MR
Vopr Onkol; 2011; 57(2):165-72. PubMed ID: 21809660
[TBL] [Abstract][Full Text] [Related]
2. [Cellular markers based on DNA damage and repair (BER, MMR), expression of MLHI, MSH2, FasR, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma].
Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB
Tsitologiia; 2011; 53(1):10-6. PubMed ID: 21473113
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
4. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy.
Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
Cancer Lett; 2006 Jul; 239(1):84-97. PubMed ID: 16143448
[TBL] [Abstract][Full Text] [Related]
5. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Boeckmann L; Schirmer M; Rosenberger A; Struever D; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Schoen MP; Brockmoeller J; Emmert S
Pharmacogenet Genomics; 2009 Oct; 19(10):760-9. PubMed ID: 19741564
[TBL] [Abstract][Full Text] [Related]
6. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
Ting S; Mairinger FD; Hager T; Welter S; Eberhardt WE; Wohlschlaeger J; Schmid KW; Christoph DC
Clin Lung Cancer; 2013 Sep; 14(5):558-567.e3. PubMed ID: 23810210
[TBL] [Abstract][Full Text] [Related]
7. Hsp27, Hsp70 and mismatch repair proteins hMLH1 and hMSH2 expression in peripheral blood lymphocytes from healthy subjects and cancer patients.
Nadin SB; Vargas-Roig LM; Drago G; Ibarra J; Ciocca DR
Cancer Lett; 2007 Jul; 252(1):131-46. PubMed ID: 17276589
[TBL] [Abstract][Full Text] [Related]
8. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
9. High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma.
Alvino E; Passarelli F; Cannavò E; Fortes C; Mastroeni S; Caporali S; Jiricny J; Cappellini GC; Scoppola A; Marchetti P; Modesti A; D'Atri S
Am J Clin Pathol; 2014 Jul; 142(1):121-32. PubMed ID: 24926095
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.
Ma S; Egyházi S; Ringborg U; Hansson J
Oncol Rep; 2002; 9(5):1015-9. PubMed ID: 12168066
[TBL] [Abstract][Full Text] [Related]
11. Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases.
Korabiowska M; König F; Verheggen R; Schlott T; Cordon-Cardo C; Romeike B; Brinck U
Anticancer Res; 2004; 24(2B):981-6. PubMed ID: 15161053
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma.
Uehara H; Miyamoto M; Kato K; Cho Y; Kurokawa T; Murakami S; Fukunaga A; Ebihara Y; Kaneko H; Hashimoto H; Murakami Y; Shichinohe T; Kawarada Y; Itoh T; Okushiba S; Kondo S; Katoh H
J Surg Oncol; 2005 Nov; 92(2):109-15. PubMed ID: 16231369
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic evaluation of DNA mismatch repair markers in 2 cases of synchronous histomorphologically distinct gastric adenocarcinomas with gastrointestinal stromal tumors of the proximal small bowel.
Athanassiou E; Vamvakopoulou DN; Zacharoulis D; Paroutoglou G; Sioutopoulou D; Tepetes K; Nomikos I; Vamvakopoulos NC
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):288-90. PubMed ID: 20090515
[TBL] [Abstract][Full Text] [Related]
14. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer.
Grabsch H; Dattani M; Barker L; Maughan N; Maude K; Hansen O; Gabbert HE; Quirke P; Mueller W
Clin Cancer Res; 2006 Mar; 12(5):1494-500. PubMed ID: 16533773
[TBL] [Abstract][Full Text] [Related]
15. Relationship between DNA mismatch repair genes expression, Ku-genes expression and ploidy-related parameters in the progression of pigmented lesions of the skin.
Korabiowska M; Tscherny M; Stachura J; Ruschenburg I; Cordon-Cardo C; Brinck U
In Vivo; 2002; 16(5):317-21. PubMed ID: 12494870
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
Braybrooke JP; Houlbrook S; Crawley JE; Propper DJ; O'Byrne KJ; Stratford IJ; Harris AL; Shuker DE; Talbot DC
Cancer Chemother Pharmacol; 2000; 45(2):111-9. PubMed ID: 10663625
[TBL] [Abstract][Full Text] [Related]
17. Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair.
Wu Q; Vasquez KM
PLoS Genet; 2008 Sep; 4(9):e1000189. PubMed ID: 18787700
[TBL] [Abstract][Full Text] [Related]
18. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of mutS homolog 2 and mutL homolog 1 affects overall survival in laryngeal squamous cell carcinoma patients: Investigation into a potential cause.
Gong HL; Shi Y; Shi Y; Wu CP; Cao PY; Zhou L; Xu C
Oncol Rep; 2013 Sep; 30(3):1371-9. PubMed ID: 23787767
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the DNA mismatch repair proteins expression in malignant melanomas.
Korabiowska M; Brinck U; Dengler H; Stachura J; Schauer A; Droese M
Anticancer Res; 2000; 20(6B):4499-505. PubMed ID: 11205295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
